Immunocore Holdings PLC
IMCR32.890USD
-0.100-0.30%
交易中 （美東）報價延遲15分鐘
1.65B總市值
虧損本益比TTM
關於 Immunocore Holdings PLC 公司
Immunocore Holdings plc 是一家位於英國的商業階段生物技術公司。該公司致力於開發 TCR 雙特異性免疫療法 ImmTAX，該療法可動員單克隆 TCR 對抗 X 疾病，旨在治療一系列疾病，包括癌症、自身免疫性疾病和傳染病。該公司擁有一個臨牀階段的全資和合作項目管線，涉及三個不同的治療領域：腫瘤學、傳染病以及自身免疫和炎症疾病。其主要產品 KIMMTRAK 是一種 TCR 治療劑，用於治療美國、歐盟、加拿大、澳大利亞和英國的不可切除或轉移性葡萄膜黑色素瘤 (mUM) 患者。其管線產品包括 IMC-F106C、IMC-F115C、IMC-F119C、IMC-F117C、IMC-F113V、IMC-I109V、IMC-SII8AI 等。其臨牀項目正在針對多種癌症患者開展，包括黑色素瘤、肺癌、胃癌等。
公司簡介
公司代碼IMCR
公司名稱Immunocore Holdings PLC
上市日期Feb 05, 2021
CEODr. Bahija Jallal, Ph.D.
員工數量493
證券類型Depository Receipt
年結日Feb 05
公司地址92 Park Drive Milton Park
城市ABINGDON
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編OX14 4RY
電話441235438600
網址https://www.immunocore.com/
公司代碼IMCR
上市日期Feb 05, 2021
CEODr. Bahija Jallal, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
股東類型
持股股東
佔比
Investment Advisor
41.30%
Investment Advisor/Hedge Fund
26.52%
Hedge Fund
22.94%
Corporation
5.15%
Private Equity
3.16%
Research Firm
2.66%
Pension Fund
0.42%
Bank and Trust
0.25%
Venture Capital
0.04%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
292
50.72M
102.46%
-9.05M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
2023Q2
236
43.68M
94.12%
-435.38K
2023Q1
218
40.62M
88.44%
-3.40M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
T. Rowe Price Investment Management, Inc.
7.05M
14.25%
+351.61K
+5.25%
Mar 31, 2025
Wellington Management Company, LLP
6.13M
12.39%
-485.33K
-7.33%
Mar 31, 2025
RTW Investments L.P.
4.87M
9.84%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
9.71%
+23.88K
+0.50%
Mar 31, 2025
PRIMECAP Management Company
2.68M
5.41%
+10.10K
+0.38%
Mar 31, 2025
Eli Lilly Vostok SA Geneva
2.55M
5.15%
--
--
Mar 21, 2025
Baker Bros. Advisors LP
2.32M
4.69%
+807.34K
+53.28%
Mar 31, 2025
Tang Capital Management, LLC
1.92M
3.87%
+360.11K
+23.15%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.89M
3.81%
-299.59K
-13.70%
Mar 31, 2025
Kynam Capital Management LP
1.70M
3.43%
+470.00K
+38.35%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
1.7%
Tema Oncology ETF
1.18%
ALPS Medical Breakthroughs ETF
1.07%
Invesco Nasdaq Biotechnology ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.1%
iShares Intl Small Cap Equity Factor ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
查看更多
Virtus LifeSci Biotech Products ETF
佔比1.7%
Tema Oncology ETF
佔比1.18%
ALPS Medical Breakthroughs ETF
佔比1.07%
Invesco Nasdaq Biotechnology ETF
佔比0.14%
ProShares Ultra Nasdaq Biotechnology
佔比0.14%
SPDR S&P International Small Cap ETF
佔比0.12%
iShares Biotechnology ETF
佔比0.1%
iShares Intl Small Cap Equity Factor ETF
佔比0.09%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
SPDR Portfolio Developed World ex-US ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
